Skip to main content
. 2013 Oct 16;8:164. doi: 10.1186/1750-1172-8-164

Table 5.

Summary of study design of all orphan medicinal products (n = 59)

  Number of OMPs (%) (n = 59)
Control arm
  At least one study with placebo or standard of care as control
44 (74.6%)
Randomization
  At least one study with random design
46 (78.0%)
Blinding
  At least one study with double blind design 34 (57.6%)